NCT00171769View on ClinicalTrials.gov

Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2006

Conditions

Persistent Nonvalvular Atrial Fibrillation

Interventions

DRUG

Certoparin

Trial Locations (2)

07936

Novartis Pharmaceuticals, East Hanover

Unknown

Investigative Centers

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY